Dihydrobenzo[b,f][1,4]thiazepine-8-carboxamide Selective D2 Antagonists
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current drugs targeting the dopamine D2 receptor lack selectivity, leading to unintended activity on non-target GPCRs and adverse effects, making it challenging to develop effective and safe therapeutic agents for disorders like schizophrenia and psychosis.
Innovation Solution
Development of dihydrobenzo[b,f][1,4]thiazepine-8-carboxamide compounds with selective affinity for the dopamine D2 receptor, providing a class of novel therapeutic agents that can selectively bind and modulate the D2 receptor with reduced off-target activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current drugs targeting the dopamine D2 receptor are used, then therapeutic effects are achieved, but selectivity is poor leading to off-target activity on non-target GPCRs and adverse effects
Solution Approach 1:
The patent modifies specific local regions of the dibenzothiazepine core structure, particularly the R1, R2, and R3 substituents, to create differentiated binding characteristics. This local quality modification allows the compound to selectively interact with the D2 receptor binding site while avoiding off-target GPCRs, thereby improving selectivity and reducing adverse effects
Solution Approach 2:
The patent systematically varies chemical parameters including the nature of substituents (R1-R3), the length of alkyl chains (m, n), and the type of heteroatoms in the core structure. These parameter changes optimize the balance between affinity for the D2 receptor and selectivity against other GPCRs, resolving the contradiction between therapeutic efficacy and selectivity
2Adaptability or versatility
If non-selective D2 receptor antagonists are used, then broad therapeutic coverage is achieved, but off-target cross-GPCR reactivity increases leading to multiple adverse effects
Solution Approach 1:
The patent divides the ligand structure into distinct functional segments: the dibenzothiazepine core provides D2 receptor affinity, while specific substituent patterns (R1-R3) provide selectivity. This segmentation allows independent optimization of therapeutic coverage through the core structure and selectivity through the substituent patterns, reducing off-target reactivity
Solution Approach 2:
The patent introduces asymmetric substitution patterns where R1, R2, and R3 are different from each other, creating a non-symmetric molecular architecture. This asymmetry enables the compound to fit selectively into the asymmetric binding pocket of the D2 receptor while not matching the binding sites of other GPCRs, thereby maintaining therapeutic coverage with reduced off-target effects
Data Source
Figure 1A~1B
Figure 2A~2B
AI summary
The disclosure includes compounds and pharmaceutically acceptable salts of Formula (I). Certain compounds and salts of Formula (I) are selective inhibitors of the Dopamine D2 receptor. The variables R1-R4, n, and L are defined herein. The disclosure also provides methods of synthesizing compounds of Formula (I) and pharmaceutical compositions containing compounds of Formula (I). Additionally the disclosure provides methods or treating patients suffering from central nervous system disorders, including Tourette's syndrome, bipolar disorder, hyperprolactinemia, tardive dyskinesia, Huntington's chorea, psychosis, depression, or schizophrenia.